SCHEMBL22774397

SCHEMBL22774397

Cc1cccc2nc(-c3ccccc3)c(NCC(=O)NO)n12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 6/20 0.55
PKLR P30613 3/20 0.55
PKM P14618 3/20 0.55
GAA P10253 12/20 0.48
KDM4E B2RXH2 7/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
ALDH1A1 P00352 7/20 0.47
MAPT P10636 6/20 0.47
LMNA P02545 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
GFER P55789 1/20 0.46
POLB P06746 2/20 0.44
MAPK1 P28482 1/20 0.44
HPGD P15428 4/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28768873 0.81 HDAC6 (0.38) TP53PKLRPKMGAAKDM4E
SCHEMBL27722222 0.81 ALDH1A1 (0.39) TP53PKLRPKMGAAKDM4E
SCHEMBL27701922 0.80 GAA (0.39) TP53PKLRPKMGAAKDM4E
SCHEMBL27722205 0.80 ALDH1A1 (0.36) TP53PKLRPKMGAAKDM4E
SCHEMBL22769579 0.79 NTRK1 (0.64) PKMGAAKDM4EALDH1A1MAPT
SCHEMBL27722391 0.78 GAA (0.40) TP53PKLRPKMGAAKDM4E
SCHEMBL27701637 0.77 HDAC1 (0.42) PKMGAAKDM4EALDH1A1MAPT
SCHEMBL1965194 0.74 GAA (0.79) TP53PKLRPKMGAAKDM4E
SCHEMBL27722187 0.73 GPR139 (0.38) GAAKDM4EALDH1A1MAPTNPSR1
SCHEMBL7833505 0.72 TP53 (0.52) TP53PKLRPKMGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388544-A1 HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES VIVORYON THERAPEUTICS N.V. (DE) 2025-12-25 US disclosed
US-20230122243-A1 Heteroaromatic inhibitors of astacin proteinases VIVORYON THERAPEUTICS N.V. (DE) 2023-04-20 US disclosed
CN-114585608-A Heteroaromatic inhibitors of astacin protease 维沃永治疗公众有限公司 2022-06-03 CN disclosed
EP-3986868-A1 HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES Vivoryon Therapeutics N.V. (DE) 2022-04-27 EP disclosed
WO-2020249760-A1 HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES VIVORYON THERAPEUTICS AG (DE) 2020-12-17 WO disclosed
CN-101163703-B Imidazo [1,2-A ] pyridine derivatives as Peptide Deformylase (PDF) inhibitors NOVARTIS AG 2010-12-15 CN disclosed
CN-101163703-A Imidazo [1, 2-A ] pyridine derivatives as Peptide Deformylase (PDF) inhibitors NOVARTIS AG (CH) 2008-04-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230122243-A1 Heteroaromatic inhibitors of astacin proteinases BMP1, DPEP1, MEP1A TP53 2741/4885PKLR 3658/4885PKM 3691/4885
US-20250388544-A1 HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES BMP1, BMPR1A, BMPR1B TP53 4150/4885PKLR 4136/4885PKM 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.